TP53 and cancer: While normal cells respond to oncogene activation with p53-p19ARF, p16-Rb, and Atf4-p27KIP-dependent OIS (165, 166), suppression of these pathways through EMT TFs provide an alternative route for cancer to maintain cell cycle progression and proceed along a tumorigenic path.